Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > keep the enthusiasm in check

<< Previous

Bullboard Posts

Next >>

Comment by Capitalistaon Mar 27, 2023 6:34pm

143 Views

Post# 35363468

RE:RE:RE:keep the enthusiasm in check

I agree, WC1000. Combination therapies seem to be emerging as the way to go in immunotherapy - there is no "killer app" available yet in this research field.

The difference in overall response between combo therapies using Pela and those not (i.e. control arms) is what gives me hope. I'm still waiting for ONC management to get Pela approved and monetize it. It's mostly up to the people there now. Hope they're up to it.

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders